Jim Wassil - Sep 1, 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role: Chief Operating Officer
Signature: Jim Wassil, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: PCVX
Transactions as of: Sep 1, 2023
Transactions value $: -$259,868
Form type: 4
Date filed: 9/6/2023, 05:33 PM
Previous filing: Jun 8, 2023
Next filing: Sep 26, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCVX	Common Stock	Options Exercise	$7.26K	+3K	+1.76%	$2.42^*	173K	Sep 1, 2023	Direct	F1
transaction	PCVX	Common Stock	Sale	-$141K	-2.68K	-1.55%	$52.75	170K	Sep 1, 2023	Direct	F2, F3
transaction	PCVX	Common Stock	Sale	-$17.2K	-323	-0.19%	$53.36	170K	Sep 1, 2023	Direct	F2, F4
transaction	PCVX	Common Stock	Tax liability	-$109K	-2.13K	-1.25%	$51.00	168K	Sep 5, 2023	Direct	F5

Showing 1 to 4 of 4 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCVX	Stock Option (right to buy)	Options Exercise	$0	-3K	-2.57%	$0.00	114K	Sep 1, 2023	Common Stock	3K	$2.42	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Includes 1,040 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2023.
F2	The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.
F3	The price reported is a weighted-average price. The shares were sold at prices ranging from $52.27 to $53.19. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4	The price reported is a weighted-average price. The shares were sold at prices ranging from $53.28 to $53.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5	Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F6	1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter.